Gonadal steroids, gonadotropins and DHEAS in young adults with familial hypercholesterolemia who had initiated statin therapy in childhood

Atherosclerosis

Volumn 241, Issue 2, 2015, Pages 427-432

  Braamskamp, Marjet J A M ^a   Kusters, D Meeike ^a   Wiegman, Albert ^a   Avis, Hans J ^a   Wijburg, Frits A ^a   Kastelein, John J P ^a   van Trotsenburg, A S Paul ^a   Hutten, Barbara A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

DHEAS; Familial hypercholesterolemia; Gonadal steroids; Gonadotropins; Statins

Indexed keywords

ATORVASTATIN; CHOLESTEROL; ESTRADIOL; EZETIMIBE; FOLLITROPIN; GONADOTROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; PLACEBO; PRASTERONE SULFATE; PRAVASTATIN; STEROID; TESTOSTERONE; TRIACYLGLYCEROL; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRASTERONE; SEX HORMONE;

ADD ON THERAPY; ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CHILD; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ESTRADIOL BLOOD LEVEL; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FOLLITROPIN BLOOD LEVEL; GONADOTROPIN BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SEX DIFFERENCE; STEROID BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; YOUNG ADULT; AGE; BLOOD; COMPARATIVE STUDY; GENETICS; HYPERLIPOPROTEINEMIA TYPE II; NETHERLANDS; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; BIOMARKERS; CHILD; DEHYDROEPIANDROSTERONE; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE, HUMAN; GONADAL STEROID HORMONES; GONADOTROPINS, PITUITARY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; LUTEINIZING HORMONE; MALE; NETHERLANDS; PRAVASTATIN; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; TESTOSTERONE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84936805966     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.05.034     Document Type: Article

References (25)

1. Rutkowski K., Sowa P., Rutkowska-Talipska J., Kuryliszyn-Moskal A., Rutkowski R. Dehydroepiandrosterone (DHEA): hypes and hopes. Drugs 2014, 74(11):1195-1207.
2. Do Vale S., Selinger L., Martins J.M., et al. The relationship between dehydroepiandrosterone (DHEA), working memory and distraction-a behavioral and electrophysiological approach. PLoS One 2014, 9(8):e104869.
3. Hill M., Dušková M., Stárka L. Dehydroepiandrosterone, its metabolites and ion channels. J. Steroid Biochem. Mol. Biol. 2015, 145C:293-314.
4. Hu J., Zhang Z., Shen W.-J., Azhar S. Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones. Nutr. Metab. (Lond.) 2010, 7(Table 1):47.
5. Miller W.L., Bose H.S. Early steps in steroidogenesis: intracellular cholesterol trafficking. J. Lipid Res. 2011, 52(12):2111-2135.
6. Goldstein J.L., Hobbs H.H., Brown M.S. PART 12: LIPIDS Chapter 120: Familial Hypercholesterolemia, Joseph L. Goldstein, Helen H. Hobbs, Michael S. Brown. The Metabolic and Molecular Bases of Inherited Disease 2001, 2863-2913. 8th ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
7. Nordestgaard B.G., Chapman M.J., Humphries S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur. Heart J. 2013, 34(45).
8. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011, 128(Suppl. l):S213-S256.
9. Kusters D.M., Avis H.J., de Groot E., et al. Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. JAMA 2014, 312(10):1055-1057.
10. Smals A.G., Weusten J.J., Benraad T.J., Kloppenborg P.W. The HMG-CoA reductase inhibitor simvastatin suppresses human testicular testosterone synthesis in vitro by a selective inhibitory effect on 17-ketosteroid-oxidoreductase enzyme activity. J. Steroid Biochem. Mol. Biol. 1991, 38(4):465-468.
11. Andreis P.G., Cavallini L., Mazzocchi G., Nussdorfer G.G. Effects of prolonged administration of lovastatin, an inhibitor of cholesterol synthesis, on the morphology and function of rat Leydig cells. Exp. Clin. Endocrinol. 1990, 96(1):15-24.
12. Böhm M., Herrmann W., Wassmann S., Laufs U., Nickenig G. Does statin therapy influence steroid hormone synthesis?. Z. Kardiol. 2004, 93(1):43-48.
13. Hyyppä M.T., Kronholm E., Virtanen A., Leino A., Jula A. Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial. Psychoneuroendocrinology 2003, 28(2):181-194.
14. Dobs A., Miller S., Neri G., et al. Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients. Metabolism 2000, 49(1):115-121.
15. Dobs A., Sarma P.S., Schteingart D. Long-term endocrine function in hypercholesterolemic patients treated with pravastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Metabolism 1993, 42(9):1146-1152.
16. H. Honjo, K. Tanaka, M. Urabe, et al. Menopause and hyperlipidemia: pravastatin lowers lipid levels without decreasing endogenous estrogens. Clin. Ther. 14(5):699-707.
17. Purvis K., Tollefsrud A., Rui H., et al. Short-term effects of treatment with simvastatin on testicular function in patients with heterozygous familial hypercholesterolaemia. Eur. J. Clin. Pharmacol. 1992, 42(1):61-64.
18. Schooling C.M., Au Yeung S.L., Freeman G., Cowling B.J. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med. 2013, 11(1):57.
19. Stein E., Illingworth D.R., Kwiterovich P.O., et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 1999, 281(2):137-144.
20. Lambert M., Lupien P.J., Gagné C., et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian lovastatin in children study group. Pediatrics 1996, 97(5):619-628.
21. De Jongh S., Ose L., Szamosi T., et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 2002, 106(17):2231-2237.
22. Wiegman A., Hutten B.A., de Groot E., et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004, 292(3):331-337.
23. Clauss S.B., Holmes K.W., Hopkins P., et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics 2005, 116(3):682-688.
24. Stein E., Gipe D., Bergeron J., et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled. Lancet 2012, 380(9836):29-36.
25. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 2007, 357(21):2109-2122.